Various Evidence-Based Hypothetical and Experimental Treatment Approaches and Their Effectiveness against COVID-19 Worldwide: A Comprehensive Literature Review
Several drugs are presently undergoing clinical studies to investigate their efficacy and safety in the handling of 2019 coronavirus disease (COVID-19). Despite of the fact, certain encouraging results have been obtained thus far, however, these treatments have resulted in controversy as these are not based on data generated from direct conventional clinical trials. As the legal requirement for approval of drug is "substantial" evidence of effectiveness demonstrated through controlled clinical trials and requires a large portion of time. A number of clinical trials are currently in progress to evaluate possible therapies, but the worldwide reaction to the COVID-19 outbreak has been mostly restricted to monitoring/ suppression. In the meantime, scientists are struggling to discover antivirals specific to the virus either by screening/ testing available broad-spectrum antiviral drugs or redevelopment of newer particular drugs based on individual coronavirus (CoV) genome. Upto date, the hypothetical and experimental treatment approaches against COVID-19 that are tested or being testing are the use of antimalarial and antibiotics, antivirals, anti-parasitic, immunomodulators, anticoagulant treatment, antihypertensive, chinese traditional medicines and others (high temperature and high humidity) as well as vaccines development. This review summarized all the literature-based treatment approaches in various ways that are implementing for the management or treatment of COVID-19.
1.Stanam A, Chaudhari M and Rayudu D. Effects of temperature on COVID-19 transmission. medRxiv 2020.
2. Organization WH. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization https://www who int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirusdisease-(covid-2019)-and-the-virus-that-causes-it 2020.
3. Khan N and Fahad S. Critical Review of the Present Situation of Corona Virus in China. Available at SSRN 3543177 2020.
4. Shokouhi M, Miralles-Wilhelm F, Anthony Amoroso M, et al. Temperature, humidity, and latitude analysis to predict po-tential spread and seasonality for COVID-19.
5. Abdulamir AS and Hafidh RR. The Possible Immunological Pathways for the Variable Immunopathogenesis of COVID--19 Infections among Healthy Adults, Elderly and Children. Electronic Journal of General Medicine 2020; 17.
6. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv 2020;202003:V1.
7. Organization WH. WHO Director-general’s remarks at the media briefing on 2019-nCoV on 11 February 2020, 2020. 2020.
8. Liu W and Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism.
9. Diao K, Han P, Pang T, et al. HRCT imaging features in representative imported cases of 2019 novel coronavirus pneumonia. Precision Clinical Medicine 2020;3:9–13.
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497–506.
11. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine 2020.
12. WHO. https://www.who.int/emergencies/diseases/novelcoronavirus-2019. (2020).
13. Singhal T. A review of coronavirus disease-2019 (COVID-19). The Indian Journal of Pediatrics 2020:1–6.
14. Tang A, Hl W, Dai Yx LK, et al. Detección de nuevos coronavirus por RT-PCR en muestras de heces de niños asintomáticos, China. Emerg Infect Dis 2020:970–1.
15. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. New England Journal of Medicine 2020;382:1177–9.
16. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama 2020;323:1061–9.
17. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020;395:507–13.
18. Prompetchara E, Ketloy C and Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020;38:1–9.
19. Naveed M, Khan SZ, Zeeshan S, et al. A new cationic palladium (II) dithiocarbamate exhibits anti-inflammatory, analgesic, and antipyretic activities through inhibition of inflammatory mediators in in vivo models. Naunyn-Schmiedeberg's archives of pharmacology 2019;392:961–77.
20. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience trends 2020;14:69–71.
21. Kim Y, Liu H, Kankanamalage ACG, et al. Reversal of the pro-gression of fatal coronavirus infection in cats by a broadspectrum coronavirus protease inhibitor. PLoS pathogens 2016;12.
22. Channappanavar R, Fett C, Mack M, et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. The Journal of Immunology 2017; 198:4046–53.
23. Zumla A, Chan JF, Azhar EI, et al. Coronaviruses—drug discovery and therapeutic options. Nature reviews Drug discovery 2016;15:327.
24. Dong L, Hu S and Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics 2020;14:58–60.
25. Gao J, Tian Z and Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends 2020.
26. Touret F and de Lamballerie X. Of chloroquine and COVID-19. Antiviral Research 2020:104762.
27. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care 2020.
28. Singh AK, Singh A, Shaikh A, et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2020.
29. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research 2020;30:269–71.
30. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 2020.
31. Wang Y-L, An C-M, Song S, et al. Cupping therapy for knee osteoarthritis: a synthesis of evidence. Complementary medicine research 2018;25:249–55.
32. Colson P, Rolain J-M and Raoult D. Chloroquine for the 2019 novel coronavirus. Int J Antimicrob Agents 2020.
33. Jie Z, He H, Xi H, et al. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia [in Chinese] 2020;10:1001-0939.
34. Gupta N, Agrawal S and Ish P. Chloroquine in COVID-19: the evidence. Monaldi Archives for Chest Disease 2020;90.
35. Sahraei Z, Shabani M, Shokouhi S, et al. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International Journal of Antimicrobial Agents 2020:105945.
36. Plantone D and Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clinical drug investigation 2018;38:653–71.
37. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery 2020;6:1–4.
38. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv 2020.
39. Yan D and Zhang Z. Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19). Chinese Clinical Trials Registry.
40. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents 2020:105949.
41. Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. British Medical Journal Publishing Group, 2020.
42. Ferner RE and Aronson JK. Chloroquine and hydroxychloroquine in covid-19. British Medical Journal Publishing Group, 2020.
43. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996;5:11–5.
44. Ohe M, Shida H, Jodo S, et al. Macrolide treatment for COVID-19: Will this be the way forward? BioScience Trends 2020.
45. Scuccimarri R, Sutton E and Fitzcharles M-A. Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic. The Journal of Rheumatology 2020.
46. Kodaz H. EDITORIAL: Successful Treatment Strategy of Turkey against Covid-19 Outbreak. 2020. DOI: 10.14744/ ejmo.2020.12345.
47. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences 2020;117:6771–6.
48. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine 2017;9.
49. University TAM. "Chemists working on drugs to treat COVID-19.", www.sciencedaily.com/releases/2020/04/200406190509.htm.
50. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine 2020.
51. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine 2020.
52. NIH. NIH clinical trial of remdesivir to treat COVID-19 begins, https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins.
53. Harrison C. Coronavirus puts drug repurposing on the fast track. Nature biotechnology 2020;38:379–81.
54. Lazer D, Pentland AS, Adamic L, et al. Life in the network: the coming age of computational social science. Science 2009;323:721–3.
55. (EMA) TEMA. Compassionate use, https://www.ema.europa. eu/en/human-regulatory/research-development/compassionate-use. (2020).
56. De Clercq E. Anti-HIV drugs. Verhandelingen-Koninklijke Academie voor Geneeskunde van Belgie 2007;69:81.
57. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four smallmolecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial agents and chemotherapy 2014;58:4875–84.
58. Chu C, Cheng V, Hung I, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252–6.
59. Tang B, Li S, Xiong Y, et al. Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient. Kidney Medicine 2020. 60. Uyeki TM. Oseltamivir treatment of influenza in children. Oxford University Press US, 2018.
61. Rosa SGV and Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Pública 2020; 44.
62. Li G and De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Publishing Group, 2020.
63. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. Jama 2020.
64. Ding Q, Lu P, Fan Y, et al. The clinical characteristics of pneumonia patients co‐infected with 2019 novel coronavirus and influenza virus in Wuhan, China. Journal of medical virology 2020.
65. Johnson J. Multi-Pronged Response to Coronavirus Global Public Health Threat, https://www.jnj.com/johnson-johnson-launches-multi-pronged-response-to-coronavirusglobal-public-health-threat.
66. Johnson. JPCoJ. Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2., https://www.janssen. com/lack-evidence-support-use-darunavir-based-treatments-sars-cov-2 (2020 March16. ).
67. Regalado A. Which Covid-19 drugs work best?, https://www. technologyreview.com/2020/03/23/950385/covid-19-coronavirus-best-drugs-in-treating-the-outbreak/. (March 23, 2020).
68. Teissier E, Zandomeneghi G, Loquet A, et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PloS one 2011;6.
69. Boriskin YS, Pécheur E-I and Polyak SJ. Arbidol: a broadspectrum antiviral that inhibits acute and chronic HCV infection. Virology journal 2006;3:56.
70. NCH. Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus -induced Pneumonia, http:// www.nhc.gov.cn/yzygj/s7653p/202002/.
71. Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Bioscience trends 2020.
72. Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. Journal of Infection 2020.
73. ChiCTR. Chinese Clinical Trial Registry. February 5, 2019.
74. Post SCM. Coronavirus: are cocktail therapies for flu and HIV the magic cure? Bangkok and Hangzhou hospitals put combination remedies to the test. 4 February 2020.
75. Caly L, Druce JD, Catton MG, et al. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research 2020:104787.
76. Götz V, Magar L, Dornfeld D, et al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Scientific reports 2016;6:1–15.
77. Jans DA, Martin AJ and Wagstaff KM. Inhibitors of nuclear transport. Current opinion in cell biology 2019;58:50–60.
78. Wen Y-C, Hsiao F-Y, Chan KA, et al. Acute respiratory infection and use of nonsteroidal anti-inflammatory drugs on risk of acute myocardial infarction: a nationwide case-crossover study. The Journal of infectious diseases 2017;215:503–9.
79. Amici C, Di Coro A, Ciucci A, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antiviral therapy 2006;11:1021.
80. Russell B, Moss C, Rigg A, et al. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? ecancermedicalscience 2020;14.
81. Wong SS and Yuen K-Y. The management of coronavirus infections with particular reference to SARS. Journal of antimicrobial chemotherapy 2008;62:437–41.
82. Hao D, He L, Qu J, et al. A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it. Zhonghua nei ke za zhi 2005;44:890–3.
83. WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected, (13 March 2020).
84. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID‐19). Medical Journal of Australia 2020.
85. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. The Lancet 2020.
86. Russell CD, Millar JE and Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet 2020;395:473–5.
87. Campbell P. Patients Receiving Glucocorticoids at Higher Risk During COVID-19 Pandemic. https://www.mdmag. com/medical-news/glucocorticoids-higher-risk-coronavirus-covid19-pandemic. (APRIL 03, 2020).
88. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases 2020;20:400–2.
89. Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. The Journal of clinical investigation 2018;128:3041–52.
90. Navarro G, Taroumian S, Barroso N, et al. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. In: Seminars in arthritis and rheumatism 2014, pp.458-469. Elsevier.
91. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti–interleukin‐6 receptor antibody in children with systemic‐onset juvenile idiopathic arthritis. Arthritis & Rheumatism 2005;52:818–25.
92. Moorlag S, Arts RJ, van Crevel R, et al. Non-specific effects of BCG vaccine on viral infections. Clinical Microbiology and Infection 2019;25:1473–8.
93. Hollm-Delgado M-G, Stuart EA and Black RE. Acute lower respiratory infection among Bacille Calmette-Guérin (BCG)– vaccinated children. Pediatrics 2014;133:e73–e81.
94. Leentjens J, Kox M, Stokman R, et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebocontrolled pilot study. The Journal of infectious diseases 2015;212:1930–8.
95. Miller A, Reandelar MJ, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020.
96. Gursel M and Gursel I. Is Global BCG Vaccination Coverage Relevant To The Progression Of SARS-CoV-2 Pandemic? Medical Hypotheses 2020:109707.
97. Shanmugaraj B, Siriwattananon K, Wangkanont K, et al. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pacific Journal of Allergy and Immunology 2020;38:10–8.
98. Yeh K-M, Chiueh T-S, Siu L, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. Journal of Antimicrobial Chemotherapy 2005;56:919–22.
99. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of infectious diseases 2015;211:80–90.
100. Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 2019;11:59.
101. Coughlin MM and Prabhakar BS. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Reviews in medical virology 2012;22:2–17.
102. Rao S, Sasser W, Diaz F, et al. Coronavirus Associated Fulminant Myocarditis Successfully Treated With Intravenous Immunoglobulin and Extracorporeal Membrane Oxygenation. Chest 2014;146:336A–336A.
103. Srivastava R, Ramakrishna C and Cantin E. Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis. The Journal of general virology 2015;96:1347.
104. Galeotti C, Kaveri SV and Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. International immunology 2017;29:491–8.
105. Jolles S, Sewell W and Misbah S. Clinical uses of intravenous immunoglobulin. Clinical & Experimental Immunology 2005;142:1–11.
106. Kaveri S, Maddur M, Hegde P, et al. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clinical & Experimental Immunology 2011;164:2–5.
107. Samson M, Fraser W and Lebowitz D. Treatments for Primary Immune Thrombocytopenia: A Review. Cureus 2019;11.
108. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends in pharmacological sciences 2004;25:306–10.
109. Shopsin B, Kaveri Sv and Bayry J. Tackling difficult Staphylococcus aureus infections: antibodies show the way. Cell host & microbe 2016;20:555–7.
110. Cheng Y, Wong R, Soo Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology and Infectious Diseases 2005;24:44–6.
111. Ko J-H, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antiviral therapy 2018;23:617–22.
112. Casadevall A and Pirofski L-a. The convalescent sera option for containing COVID-19. The Journal of clinical investigation 2020;130:1545–8.
113. Zafar D. DRAP permits clinical trials of plasma therapy for treatment, https://www.thenews.com.pk/print/642195- drap-permits-clinical-trials-of-plasma-therapy-for-treatment-dr-zafar
114. Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. The Journal of Clinical Investigation 2020.
115. EDT TOC. "Cuba uses "wonder drug" to fight coronavirus around the world despite U.S. sanctions", (March 24, 2020).
116. Sameh Y. China Is Using Cuba’s Interferon Alfa 2B Against Coronavirus, https://see.news/china-is-using-cubas-interferon-alfa-2b-against-coronavirus. (March 19, 2020).
117. Liu T, Zhang J, Yang Y, et al. The potential role of IL-6 in monitoring coronavirus disease 2019. Available at SSRN 3548761 2020.
118. Gong J, Dong H, Xia SQ, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. MedRxiv 2020.
119. Liu B, Li M, Zhou Z, et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Journal of Autoimmunity 2020:102452.
120. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis 2020.
121. Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis 2019;17:1989–94.
122. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 2020.
123. Iba T, Di Nisio M, Levy JH, et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ open 2017;7:e017046.
124. Schmitt FCF, Manolov V, Morgenstern J, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Annals of intensive care 2019;9:19.
125. Gupta N, Zhao Y-Y and Evans CE. The stimulation of thrombosis by hypoxia. Thrombosis research 2019.
126. Luo W, Yu H, Gou J, et al. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Pathology & Pathobiology 2020;2020020407.
127. Poterucha TJ, Libby P and Goldhaber SZ. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thrombosis and haemostasis 2017;117:437–44.
128. Imai Y, Kuba K and Penninger JM. The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in mice. Experimental physiology 2008;93:543–8.
129. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. Journal of Travel Medicine 2020.
130. Patel AB and Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? Jama 2020.
131. Luo H, Tang Q-l, Shang Y-x, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chinese journal of integrative medicine 2020:1–8.
132. Lau JT, Leung P, Wong E, et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenzarelated symptoms, and improve quality of life: a prospective cohort study. Journal of Alternative & Complementary Medicine 2005;11:49–55.
133. Du CY, Zheng KY, Bi CW, et al. Yu Ping Feng San, an ancient Chinese herbal decoction, induces gene expression of anti‐ viral proteins and inhibits neuraminidase activity. Phytotherapy research 2015;29:656–61.
134. Wang C, Cao B, Liu Q-Q, et al. Oseltamivir compared with the Chinese traditional therapy Maxingshigan–Yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Annals of internal medicine 2011;155:217–25.
135. Liu L-S, Lei N, Lin Q, et al. The Effects and Mechanism of Yinqiao Powder on Upper Respiratory Tract Infection. International Journal of Biotechnology for Wellness Industries 2015;4:57–60.
136. Ou A-h, Lu C-j, Li J-q, et al. Analysis on the Chinese medicine syndromes and demographic characteristics of patients with influenza-like illness in clinics of China. Chinese journal of integrative medicine 2014;20:101–6.
137. ftgfhh. https://www.jnj.com/johnson-johnson-launchesmulti-pronged-response-to-coronavirus-global-publichealth-threat. jjjjj 3434.
138. Zhang H and Zhu Y. One highly suspected case of novel coronavirus pneumonia treated by Integrated Traditional Chinese and Western medicine and nucleic acid analysis. Tianjin Journal of Traditional Chinese Medicine http://kns cnki net/kcms/detail/121349;20200227:004.
139. Ghalhari GF and Mayvaneh F. Effect of Air Temperature and Universal Thermal Climate Index on Respiratory Diseases Mortality in Mashhad, Iran. Archives of Iranian Medicine (AIM) 2016;19.
140. Gosling SN, McGregor GR and Lowe JA. Climate change and heat-related mortality in six cities Part 2: climate model evaluation and projected impacts from changes in the mean and variability of temperature with climate change. Interna-tional journal of biometeorology 2009;53:31–51.
141. Li M, Zhou M, Yang J, et al. Temperature, temperature extremes, and cause-specific respiratory mortality in China: a multi-city time series analysis. Air Quality, Atmosphere & Health 2019;12:539–48.
142. Kim J, Shin J, Lim Y-H, et al. Comprehensive approach to understand the association between diurnal temperature range and mortality in East Asia. Science of the Total Environment 2016;539:313–21.
143. Sharafkhani R, Khanjani N, Bakhtiari B, et al. Diurnal temperature range and mortality in Tabriz (the northwest of Iran). Urban Climate 2019;27:204–11.
144. Wallis P and Nerlich B. Disease metaphors in new epidemics: the UK media framing of the 2003 SARS epidemic. Social science & medicine 2005;60:2629–39.
145. Park JE, Son WS, Ryu Y, et al. Effects of temperature, humidity, and diurnal temperature range on influenza incidence in a temperate region. Influenza and other respiratory viruses 2020;14:11–8.
146. Metz JA and Finn A. Influenza and humidity–Why a bit more damp may be good for you! Journal of Infection 2015;71:S54–S58.
147. Oliveiros B, Caramelo L, Ferreira NC, et al. Role of temperature and humidity in the modulation of the doubling time of COVID-19 cases. medRxiv 2020.
148. Davis RE, McGregor GR and Enfield KB. Humidity: A review and primer on atmospheric moisture and human health. Environmental research 2016;144:106–16.
149. Barreca AI and Shimshack JP. Absolute humidity, temperature, and influenza mortality: 30 years of county-level evidence from the United States. American journal of epidemiology 2012;176:S114–S122.
150. Lowen AC and Mubareka S. John Steel, and Peter Palese. 2007.“Influenza virus transmission is dependent on relative humidity and temperature.” PLoS Pathogens;3:e151.
151. Thomas SJ, L’Azou M, Barrett AD, et al. Fast-track Zika vaccine development—is it possible? New England Journal of Medicine 2016;375:1212–6.
152. Gouglas D, Le TT, Henderson K, et al. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. The Lancet Global Health 2018;6:e1386–e1396.
153. WHO. DRAFT landscape of COVID-19 candidate vaccines https://www.who.int/blueprint/priority-diseases/keyaction/Novel-Coronavirus_Landscape_nCoV-4april2020. pdf?ua=1 (4 April 2020).
154. Dhama K, Sharun K, Tiwari R, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics 2020:1–7.